Yutaka Yamada
5PUBLICATIONS
7CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Jul 20, 2023
Using the neutrophil-to-lymphocyte ratio to predict the outcome of individuals with nonsquamous non-small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed.Hisao Imai, Satoshi Wasamoto, Takeshi Tsuda
|Sep 05, 2022
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.Ken Masubuchi, Hisao Imai, Satoshi Wasamoto
|Jun 14, 2022
Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer.Ayako Shiono, Hisao Imai, Satoshi Wasamoto
|Sep 28, 2021
Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations.Yutaka Yamada, Hisao Imai, Tomohide Sugiyama
|Aug 20, 2021
Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.Hisao Imai, Takayuki Kishikawa, Hiroyuki Minemura
Pageof 1
